Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol
- 9 August 2010
- journal article
- research article
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 15 (5) , 314-325
Abstract
Objective To compare the effects on ovarian activity of two oral contraceptives containing nomegestrol acetate (NOMAC)/17β-oestradiol (E2) or drospirenone (DRSP)/ethinylestradiol (EE). Methods In this open-label, randomised, six-cycle study, 32 subjects using NOMAC/E2 (2.5–1.5 mg; 24/4-day regimen) were compared to 16 subjects using DRSP/EE (3 mg–30 μg; 21/7-day regimen). Measurements included serum oestradiol, progesterone, follicle stimulating hormone (FSH) and luteinising hormone (LH), and ultrasonography of follicular diameter. Results No ovulations occurred during treatment. Progesterone was fully suppressed, with mean maximum values <2 nmol/l in both groups over all cycles. For NOMAC/E2, mean maximum follicular diameter decreased from 19.3 mm before treatment to between 6.9 and 8.2 mm during treatment, with no subject having a follicular diameter ≥15 mm. For DRSP/EE, a decrease from 19.6 to between 7.4 and 10.8 mm was observed, with two subjects (12.5%) having a maximum follicle diameter ≥15 mm. These findings were consistent with observed FSH reductions; full suppression of LH surges was observed in both groups. Post-treatment return of ovulation in both groups occurred on average 21 days after the last active tablet intake. Conclusions NOMAC/E2 achieves consistent ovulation inhibition, with suppressive effects on the ovaries at least similar to those of DRSP/EE.Keywords
This publication has 22 references indexed in Scilit:
- After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptivesThe European Journal of Contraception & Reproductive Health Care, 2010
- New progestagens for contraceptive useHuman Reproduction Update, 2005
- Pharmacology of estrogens and progestogens: influence of different routes of administrationClimacteric, 2005
- Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparationsContraception, 1999
- Approaches to the replacement of ethinylestradiol by natural 17β-estradiol in combined oral contraceptivesExperimental and Toxicologic Pathology, 1998
- Hormonal Contraception and Risk of Cardiovascular DiseaseContraception, 1998
- Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activityThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Oral contraceptive containing natural estradiol for premenopausal womenMaturitas, 1995
- Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17β-estradiolFertility and Sterility, 1993
- A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogensContraception, 1980